EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry

Alina Boteanu, Leticia Leon iD, Silvia Pérez Esteban, Elena Rabadán Rubio, Marina Pavía Pascual, Gema Bonilla, Carmen Bonilla González-Laganá, Antia García Fernandez, Sheila Recuero Diaz, Lucia Ruiz Gutierrez, José Javier Sanmartín Martínez, Natalia de la Torre-Rubio und 8 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac148 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Alina Boteanu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department and IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19, Arthritis, Rheumatoid, Antirheumatic Agents, Rheumatic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this study is to evaluate risk factors for severe coronavirus disease 2019 (COVID-19) in patients with immune-mediated rheumatic diseases, stratified by systemic autoimmune conditions and chronic inflammatory arthritis.

Methods

An observational, cross-sectional multicentre study was performed. Patients from 10 rheumatology departments in Madrid who presented with severe acute respiratory syndrome coronavirus-2 infection between February 2020 and May 2021 were included. The main outcome was COVID-19 severity (hospital admission or mortality). Risk factors for severity were estimated, adjusting for covariates (socio-demographic, clinical, and treatments), using logistic regression analyses.

Results

In total, 523 patients with COVID-19 were included, among whom 192 (35.6%) patients required hospital admission and 38 (7.3%) died. Male gender, older age, and comorbidities such as diabetes mellitus, hypertension, and obesity were associated with severe COVID-19. Corticosteroid doses >10 mg/day, rituximab, sulfasalazine, and mycophenolate use, were independently associated with worse outcomes. COVID-19 severity decreased over the different pandemic waves. Mortality was higher in the systemic autoimmune conditions (univariate analysis, P < .001), although there were no differences in the overall severity in the multivariate analysis.

Conclusions

This study confirms and provides new insights regarding the harmful effects of corticosteroids, rituximab, and other therapies (mycophenolate and sulfasalazine) in COVID-19. Methotrexate and anti-tumour necrosis factor therapy were not associated with worse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Arthritis, RheumatoidAntirheumatic AgentsRheumatic DiseasesHumansMaleRituximabSulfasalazineCross-Sectional StudiesSARS-CoV-2Immunosuppressive AgentsRegistries

Stichwörter der Autor:innen

COVID-19Immune-mediated rheumatic diseaseschronic inflammatory arthritissystemic autoimmune conditionstargeted synthetic/biological disease–modifying antirheumatic drugs

Substanzen

RituximabSulfasalazineAntirheumatic AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Rheumatology Department and IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Rheumatology Department and IDISSC, Hospital Clínico San Carlos, Madrid, Spain.
  • Health Sciences, Universidad Camilo José Cela, Madrid, Spain.
  • Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Rheumatology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
  • Rheumatology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

ORCID-Profile: Leticia Leon

Zitieren

APA

Boteanu, A., Leon, L., Pérez Esteban, S., Rabadán Rubio, E., Pavía Pascual, M., Bonilla, G., Bonilla González-Laganá, C., García Fernandez, A., Recuero Diaz, S., Ruiz Gutierrez, L., Sanmartín Martínez, J. J., de la Torre-Rubio, N., Nuño, L., Sánchez Pernaute, O., Del Bosque, I., Lojo Oliveira, L., Rodríguez Heredia, J. M., Clemente, D., Abasolo, L., & Bachiller-Corral, J. (2023). Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry. Modern Rheumatology. https://doi.org/10.1093/mr/roac148

Vancouver

Boteanu A, Leon L, Pérez Esteban S, Rabadán Rubio E, Pavía Pascual M, Bonilla G, et al. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry. Modern Rheumatology. 2023. doi:10.1093/mr/roac148

BibTeX
@article{Boteanu2023,
  author = {Boteanu, Alina and Leon, Leticia and Pérez Esteban, Silvia and Rabadán Rubio, Elena and Pavía Pascual, Marina and Bonilla, Gema and Bonilla González-Laganá, Carmen and García Fernandez, Antia and Recuero Diaz, Sheila and Ruiz Gutierrez, Lucia and Sanmartín Martínez, José Javier and de la Torre-Rubio, Natalia and Nuño, Laura and Sánchez Pernaute, Olga and Del Bosque, Iván and Lojo Oliveira, Leticia and Rodríguez Heredia, José Manuel and Clemente, Daniel and Abasolo, Lydia and Bachiller-Corral, Javier},
  title = {Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac148}
}
Kostenlos starten →